Testing effectiveness (Phase 2)Active Not RecruitingNCT04584983
What this trial is testing
Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
Who this might be right for
Bilirubin Encephalopathy
The University of Texas Health Science Center, Houston 134